Germline BRCA Testing and Targeting With Adjuvant Olaparib in HER2- EBC
  • CME
  • CE

In this module, an expert reviews germline BRCA mutations, biomarker testing, and adjuvant olaparib in the management of patients with gBRCA1/2-mutated, HER2-negative, high-risk early breast cancer.
Yara Abdou, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.75 Nursing contact hours
Pharmacists: 0.75 contact hours (0.075 CEUs)
Released: May 17, 2022 Expiration: May 16, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply guidelines and expert recommendations for germline BRCA testing in patients with early-stage breast cancer
  • Develop genetic testing and risk assessment strategies that incorporate expert guidance to identify all patient subgroups with EBC at high risk for recurrence
  • Discuss with patients how their risk of progression affects prognosis and therapeutic planning
  • Identify patients with early-stage breast cancer most likely to benefit from recently approved neoadjuvant/adjuvant targeted or immunotherapy agents
  • Plan adjuvant therapy using PARP inhibitor, immune checkpoint inhibitor, and/or CDK4/6 inhibitors for select patients with EBC
  • Manage treatment-related adverse events in the early-stage breast cancer setting associated with new treatment options to improve adherence, the patient experience and to optimize outcomes

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
AstraZeneca
Lilly
Merck Sharp & Dohme Corp.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Yara Abdou, MD

Assistant Professor
Division of Medical Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Yara Abdou, MD, has disclosed that she has received consulting fees from Exact Sciences.

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.
Elizabeth O’Connell, PhD
Elizabeth O’Connell, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Kay Orbaugh, MSN, NP, AOCNP, has disclosed she has received speaker fees from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Gilead Sciences, Lilly, Morphosys, Pfizer, Regeneron, and Sanofi.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed that he had individual publicly traded stocks/options in AstraZeneca.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for oncologists, nurses, pharmacists, and other healthcare professionals who care for patients with breast cancer.

Goal

The goal of this activity is to educate oncologists, oncology nurses, pharmacists, and other healthcare professionals about recent developments in the treatment of patients with early breast cancer in order to optimally individualize therapy and improve outcomes.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-140-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 50% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 17, 2022, through May 16, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Enter details about your patient with HER2+ MBC into this online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Komal Jhaveri, MD Heather McArthur, MD, MPH Sara Tolaney, MD, MPH Released: November 23, 2022

Expert commentary with Dr Charles Geyer on the essential need for BRCA testing in early breast cancer to guide adjuvant olaparib decisions, from Clinical Care Options (CCO) and ProCE

Charles E. Geyer, Jr., MD Released: November 17, 2022

A patient describes her journey with early breast cancer and the critical role of good communication between patients and their healthcare providers in this short video by Clinical Care Options (CCO)

person default Zoe Lanham Released: November 16, 2022

Downloadable slides on multidisciplinary approaches to managing high-risk, HR-positive/HER2-negative early breast cancer, from Clinical Care Options, (CCO)

Erika P. Hamilton, MD
Program Director
Joyce O'Shaughnessy, MD
Program Director
Released: November 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings